Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human, open-label, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.

Next Previous
Trial Profile

A first-in-human, open-label, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EGL-003 (Primary)
  • Indications Atopic dermatitis; Autoimmune disorders; Cancer
  • Focus Adverse reactions; First in man
  • Sponsors Egle Therapeutics

Most Recent Events

  • 30 Sep 2026 Results presented in the Egle Therapeutics media release.
  • 15 Sep 2026 According to an Egle Therapeutics media release, data from this study will be presented at the 35th Congress of the European Academy of Dermatology and Venereology (EADV), taking place September 30- October 3, 2026, in Vienna, Austria.
  • 15 Sep 2026 Status changed from recruiting to completed, according to Egle Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top